Intratumoral Lipopolysaccharide Positivity Related to Tumor-Associated Macrophage Infiltration and Poor Prognosis in Esophageal Squamous Cell Carcinoma
- PMID: 40632203
- DOI: 10.1245/s10434-025-17773-0
Intratumoral Lipopolysaccharide Positivity Related to Tumor-Associated Macrophage Infiltration and Poor Prognosis in Esophageal Squamous Cell Carcinoma
Abstract
Background: Prognosis in esophageal squamous cell carcinoma (ESCC) is influenced by the tumor microenvironment, where CD163-positive M2-like tumor-associated macrophages promote immune suppression and tumor progression. Lipopolysaccharide (LPS), markers of intratumoral microbiota, activate nuclear factor-kappa B (NF-κB) signaling and inflammation. Inflammation-based prognostic scores, such as the lymphocyte-to-monocyte ratio (LMR), are poor prognostic factors in various types of cancers. This study evaluated the impact of intratumoral LPS on systemic inflammation and the tumor microenvironment in ESCC.
Methods: Surgical specimens from 134 patients with ESCC were analyzed. Immunohistochemical staining was performed to evaluate intratumoral LPS positivity and its associations with clinicopathological factors, prognosis, inflammation-based prognostic scores, including LMR, CD163-positive TAM infiltration, and nuclear NF-κB expression, and tumoral vimentin expression as an epithelial-mesenchymal transition/mesenchymal marker in patients with ESCC.
Results: LPS was identified in ESCC cell nuclei and cytoplasm. High intratumoral LPS positivity was associated with N factor progression, high NF-κB nuclear positivity, low LMR, and high stromal CD163-positive TAM infiltration, and it served as an independent poor prognostic factor. Lipopolysaccharide positivity was significantly related to poor prognosis in CD163-positive TAM cases, compared with LPS negativity.
Conclusions: Detection of LPS in resected ESCC tissues could be a reliable biomarker for identifying high-risk patients with aggressive tumor characteristics, systemic inflammation, and impaired tumor immunity.
Keywords: Esophageal squamous cell carcinoma; Intratumoral microbiota; Lipopolysaccharide; Tumor microenvironment; Tumor-associated macrophage.
© 2025. Society of Surgical Oncology.
Conflict of interest statement
Disclosure: The authors declare no conflicts of interest associated with this manuscript.
Similar articles
-
Low TIF1γ Expression is Associated with Cancer Aggressiveness and Shorter Recurrence-Free Survival in Patients with Esophageal Squamous Cell Carcinoma.Ann Surg Oncol. 2025 Aug;32(8):6023-6030. doi: 10.1245/s10434-025-17238-4. Epub 2025 Apr 10. Ann Surg Oncol. 2025. PMID: 40208493
-
VSIG4 as a tumor-associated macrophage marker predicting adverse prognosis in diffuse large B-cell lymphoma.Front Immunol. 2025 Jun 5;16:1567035. doi: 10.3389/fimmu.2025.1567035. eCollection 2025. Front Immunol. 2025. PMID: 40539047 Free PMC article.
-
Prognostic and predictive value of CD163 expression and the CD163/CD68 expression ratio for response to adjuvant chemotherapy in patients with surgically resected lung squamous cell carcinoma.Thorac Cancer. 2023 Jul;14(20):1911-1920. doi: 10.1111/1759-7714.14937. Epub 2023 May 20. Thorac Cancer. 2023. PMID: 37208929 Free PMC article.
-
Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis.BMC Cancer. 2016 Nov 11;16(1):877. doi: 10.1186/s12885-016-2940-7. BMC Cancer. 2016. PMID: 27835987 Free PMC article.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
Cited by
-
ASO Author Reflections: Intratumoral Lipopolysaccharide as a Novel Biomarker of the Tumor Microenvironment and Prognosis in Esophageal Squamous Cell Carcinoma.Ann Surg Oncol. 2025 Jul 18. doi: 10.1245/s10434-025-17919-0. Online ahead of print. Ann Surg Oncol. 2025. PMID: 40681808 No abstract available.
References
-
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660 . - DOI - PubMed
-
- Lander S, Lander E, Gibson MK. Esophageal cancer: overview, risk factors, and reasons for the rise. Curr Gastroenterol Rep. 2023;25:275–9. https://doi.org/10.1007/s11894-023-00899-0 . - DOI - PubMed
-
- Morgan E, Soerjomataram I, Rumgay H, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology. 2022;163:649-58.e2. https://doi.org/10.1053/j.gastro.2022.05.054 . - DOI - PubMed
-
- Puhr HC, Prager GW, Ilhan-Mutlu A. How we treat esophageal squamous cell carcinoma. ESMO Open. 2023;8:100789. https://doi.org/10.1016/j.esmoop.2023.100789 . - DOI - PubMed - PMC
-
- Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. The microbiome and human cancer. Science. 2021;371:eabc4552. https://doi.org/10.1126/science.abc4552 . - DOI - PubMed - PMC
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials